Quetiapine Fumarate (SEROQUEL) Compared to Placebo in the Treatment of Adolescent Patients with Schizophrenia - ANCHOR 112
Study identifier:D1441C00112
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A 6-week, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Phase 3b Study of the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL™) Immediate-release Tablets Compared with Placebo in Adolescents with Schizophrenia (abbreviated)
Medical condition
schizophrenia
Phase
Phase 3
Healthy volunteers
No
Study drug
quetiapine fumarate tablets
Sex
All
Actual Enrollment
249
Study type
Interventional
Age
13 Years - 17 Years
Date
Study Start Date: 01 Sept 2004
Primary Completion Date: -
Study Completion Date: 01 Jun 2007
Study design
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
Seroquel Medical Science Director
AstraZeneca
